Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
Open Access
- 24 September 2020
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 96 (1) , E5-+
Abstract
No abstract availableKeywords
Funding Information
- Karyopharm Therapeutics (NCT02336815)
This publication has 5 references indexed in Scilit:
- Treatment Options for Triple-class Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2020
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).Journal of Clinical Oncology, 2019
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2018
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276Leukemia, 2013